However, the overactivation of NRF2 upregulates these drug-metabolizing enzymes, leading to enhanced drug metabolism and clearance in cancers like lung, colorectal, breast, and prostate cancer. This evidence concerns the gene NFE2L2 and Familial prostate cancer.